Deutsche Bank Analysts Give Bayer (BAYN) a €127.00 Price Target

Deutsche Bank set a €127.00 ($147.67) price target on Bayer (FRA:BAYN) in a research note released on Wednesday morning. The firm currently has a buy rating on the healthcare company’s stock.

A number of other analysts have also issued reports on BAYN. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the stock a buy rating in a research note on Friday, June 1st. Jefferies Financial Group set a €123.00 ($143.02) price target on shares of Bayer and gave the stock a buy rating in a research note on Monday, June 4th. Sanford C. Bernstein set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a buy rating in a research note on Monday, June 4th. Kepler Capital Markets set a €104.00 ($120.93) price target on shares of Bayer and gave the stock a neutral rating in a research note on Monday, June 4th. Finally, Warburg Research set a €118.00 ($137.21) price target on shares of Bayer and gave the stock a neutral rating in a research note on Monday, June 4th. Ten investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Bayer currently has an average rating of Buy and an average price target of €101.36 ($117.86).

Shares of FRA:BAYN opened at €71.82 ($83.51) on Wednesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply